World Investment Advisors LLC Invests $4.07 Million in Cencora, Inc. (NYSE:COR)

World Investment Advisors LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,090 shares of the company's stock, valued at approximately $4,072,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Pacer Advisors Inc. increased its holdings in Cencora by 6,855.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after purchasing an additional 2,035,679 shares during the period. Bank of Montreal Can increased its stake in shares of Cencora by 136.8% during the second quarter. Bank of Montreal Can now owns 641,887 shares of the company's stock valued at $153,623,000 after buying an additional 370,841 shares during the period. American Century Companies Inc. raised its holdings in shares of Cencora by 155.0% during the second quarter. American Century Companies Inc. now owns 598,438 shares of the company's stock valued at $134,828,000 after acquiring an additional 363,796 shares in the last quarter. Wellington Management Group LLP lifted its stake in Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock worth $1,168,927,000 after acquiring an additional 338,452 shares during the period. Finally, Two Sigma Advisers LP boosted its holdings in Cencora by 21.7% in the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock valued at $368,771,000 after acquiring an additional 292,600 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This represents a 7.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have sold 93,018 shares of company stock worth $22,478,942. 15.80% of the stock is owned by insiders.

Cencora Stock Performance

Shares of Cencora stock traded up $0.12 during trading on Friday, hitting $232.24. 780,788 shares of the company's stock traded hands, compared to its average volume of 1,386,901. Cencora, Inc. has a 1 year low of $195.83 and a 1 year high of $253.27. The business has a 50-day simple moving average of $238.36 and a 200-day simple moving average of $233.91. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The stock has a market capitalization of $44.89 billion, a P/E ratio of 30.92, a PEG ratio of 1.54 and a beta of 0.45.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. This is an increase from Cencora's previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.95%. Cencora's dividend payout ratio is 29.29%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Mizuho started coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 target price for the company. Bank of America restated a "neutral" rating and issued a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Barclays increased their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Finally, Leerink Partners dropped their price objective on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, Cencora has an average rating of "Moderate Buy" and an average target price of $275.60.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.